Webinars and Commercial Conversations — Register Now

Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.

Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC

CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.

Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers

Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute

CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

Manage Subscription

To receive CAP TODAY magazine, please subscribe here.
For change of address, mail new information to: CAP TODAY Circulation, 325 Waukegan Road, Northfield, IL 60093-2750 or visit here.

Product Spotlight

Werfen

Aptiva

Company

Werfen

Name of instrument

Aptiva

Email

AID.marketing.na@werfen.com

City, State

San Diego, CA

Phone

858-586-9900   

Website

http://www.werfen.com

Type of instrument

immunoassay

List price/First year sold in U.S.

—/2021

Targeted hospital bed size/Targeted test volume

200/daily: 150; monthly: 3,000; annual: 36,000

Company manufactures instrument

yes

Other models in this family of analyzers

—

No. of units in clinical use in U.S./Outside U.S. (countries)

—/50

Dimensions (H × W × D)/Instrument footprint

30 × 60 × 24 in./10 sq. ft.

Weight empty/Weight fully loaded

275 lbs./285 lbs.

No. of different measured assays onboard simultaneously

20 (20 can be run and calibrated at one time)

No. of user-definable (open chemistry) channels

0

Test throughput per hour/Assay run time

up to 720/30 min.

No. of direct ion-selective electrode channels

—

Detection methods

—

Stat time until completion/specimen throughput for Ion-selective electrode

—

Stat time until completion/specimen throughput for Ion-selective electrode basic metabolic panel

—

Stat time until completion/specimen throughput for Ion-selective electrode complete metabolic panel

—

Typical time delay from ordering stat test until aspiration of sample

—

Fully automated microplate immunoassay system

no

Methodologies supported

fluorescence

Separation methodologies

magnetic particle

Stat time until completion of a ß-hCG test

—

Stat time until completion of a cTn test

—

• Typical time delay from test order to aspiration of sample

—

Reagents refrigerated onboard/Reagents ready to use

yes (5°C)/yes

Reagent lot tracking/Reagent inventory

yes/yes

Reagent form/Reagents barcoded

liquid chemistry (closed reagent system)/yes

Separate reagent pack for each specimen/for each test run

no/no

Walkaway capability/Walkaway duration

yes/6.5 hrs.

Design of sample-handling system

rack

Uses washable cuvettes/Uses disposable cuvettes

no/yes (can store up to 728 cuvettes)

Min.–max. sample volume that can be aspirated at one time 

10–100 µL

Min. reaction volume/Min. specimen volume/Min. dead volume

10 µL/10 µL/50 µL

Dedicated pediatric sample cup

no

Primary tube sampling

yes

Accommodates most standard tube sizes/Accepts nonstandard tube sizes

yes/yes

Pierces caps on primary tubes

no

Protects against probe collision

yes

Detects clots/liquid level/short sample

yes/yes/yes

Detection or quantitation for hemolysis, icterus, lipemia, clots

detection for clots; hemolysis, icterus, lipemia not available

Dilutes patient samples onboard/Susceptibility to carryover

no/—

Automatic rerun capability

yes

Sample volume can be diluted to rerun out-of-linear-range high results

yes

Sample volume can be concentrated to rerun out-of-linear-range low results

yes

Autocalibration/Multipoint calibration supported

yes (calibrants can be stored onboard)/yes

Typical calibration frequency for ISE/therapeutic drugs/drugs of abuse/general chemistries/immunoassays

—/—/—/—/each lot or 6 months

Automatic programmable start/Automatic programmable shutdown

yes (10 min. warm-up time)/yes

Onboard real-time QC/Onboard software capability to review QC

yes/yes

Supports multiple QC lot numbers per analyte

yes

Waste management

automated collection onboard instrument or direct to drain

Sample barcode-reading capability/Autodiscrimination

yes (Interleaved 2 of 5, UPC, Codabar, Code 39, Code 128)/yes

Lab can control analyzer from remote computer

no

Instrument can diagnose its own malfunctions

no (operator intervention required to order parts)

System malfunctions can be diagnosed via remote monitoring

yes

UPS backup power supply

yes

Data-management capability/LIS or EHR systems interfaced

onboard/Oracle Health, Clinisys, Meditech

LIS interface provided/Bidirectional interface capability

yes/yes (broadcast download and host query)

Modem servicing provided/Service engineer on-site response time

yes/12 hrs.

Mean time between failures

180 days (displays error codes for troubleshooting)

Average scheduled maintenance time by lab personnel

daily: 10 min.; weekly: 15 min.; monthly: 20 min.

Maintenance records kept onboard for user/vendor

yes/yes (includes audit trail of who replaced parts)

Maintenance training demonstration module onboard

yes

Training included with purchase/Avg. time for basic user training

yes (2 training slots)/3 days (at customer site)

Advanced operator training/Extra charge for follow-up or advanced training

yes (at customer site)/no

Warranty provided/Cost of annual service contract (24 h/7 d)

yes (1 year)/—

Distinguishing features (supplied by company)

multianalyte system allows simultaneous analysis of up to 12 analytes;introduces novel analytes to improve utility of autoimmune diagnosis; 6.5 hour consumable walkaway time; generates up to 720 results per hour

Note

all information listed was provided to CAP TODAY in 2025; company did not provide updated information by 2026 entry deadline

More products
in this guide

Alinity ci-series
ASI Evolution RPR Syphilis Analyzer
DxI 9000 Access Immunoassay Analyzer
Pictus 700 (P700)
Agility Automated ELISA System
AIX1000 Agglutination Instrument
Yumizen C1200
Yumizen C560
VITROS 3600 Immunodiagnostic System
VITROS 4600 Chemistry System
VITROS XT 7600 Integrated System
cobas pro integrated solutions
dIFine P30 Processor
IMMULITE 2000 XPi Immunoassay System
Phadia 250 Laboratory System
QUANTA-Lyser 3000